Fusion Antibodies (LON:FAB) Shares Down 2.4% – Here’s Why

Shares of Fusion Antibodies plc (LON:FAB) fell 2.4% during trading on Thursday . The stock traded as low as GBX 3.90 ($0.05) and last traded at GBX 4.10 ($0.05). 457,418 shares were traded during mid-day trading, a decline of 59% from the average session volume of 1,104,111 shares. The stock had previously closed at GBX 4.20 ($0.05).

Fusion Antibodies Trading Up 1.2 %

The stock’s 50 day simple moving average is GBX 3.94 and its two-hundred day simple moving average is GBX 3.56. The stock has a market capitalization of £3.96 million, a PE ratio of -103.75 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a current ratio of 3.87 and a quick ratio of 2.36.

Insider Activity at Fusion Antibodies

In other news, insider Richard John Buick acquired 94,825 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was bought at an average price of GBX 3 ($0.04) per share, with a total value of £2,844.75 ($3,703.14). In related news, insider Adrian Kinkaid purchased 120,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £3,600 ($4,686.28). Also, insider Richard John Buick purchased 94,825 shares of Fusion Antibodies stock in a transaction dated Monday, September 9th. The stock was bought at an average price of GBX 3 ($0.04) per share, with a total value of £2,844.75 ($3,703.14). Over the last quarter, insiders have bought 298,553 shares of company stock worth $979,387. Insiders own 11.39% of the company’s stock.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.